Biopharma
PrivateA de-risked balance sheet ($2.3B cash, two partnered Phase-3 obesity assets) wrapped around a lead drug the market has already judged "undifferentiated" — the bet is that tolerability-led amylin still wins share in a >$150B market, not that petrelintide out-loses Lilly/Novo. Watchlist, not conviction-long, until ZUPREME-2 (H2'26) and a Phase-3 design tell us whether 10.7% mono + combo upside is the real story.
Research
The verdict
A de-risked balance sheet ($2.3B cash, two partnered Phase-3 obesity assets) wrapped around a lead drug the market has already judged "undifferentiated" — the bet is that tolerability-led amylin still wins share in a >$150B market, not that petrelintide out-loses Lilly/Novo. Watchlist, not conviction-long, until ZUPREME-2 (H2'26) and a Phase-3 design tell us whether 10.7% mono + combo upside is the real story.
Zealand Pharma is a Danish peptide-engineering house (HQ Copenhagen; founded 1998) that has spent 25 years turning its proprietary peptide-design platform into metabolic and GI drugs — and then monetizing them through Big-Pharma partners rather than carrying full commercial risk itself. CEO Adam Steensberg (M.D., CEO since Mar 2022) reframed it in Dec 2025 as "Metabolic Frontier 2030" — an ambition to be a leader in obesity/metabolic health with five product launches by 2030.
The business model is a platform-plus-partnership engine, three revenue layers:
The one-sentence version: Zealand is no longer "a biotech with a pipeline" — post-Roche it is a financed, de-risked optionality basket on the amylin + glucagon-dual obesity wave, where partners fund the Phase 3s and Zealand keeps ~50% US economics on the lead and royalties on the rest. Customers (in pharma terms) are the partners (Roche, Boehringer, Novo), not patients — Zealand sells discovery + early clinical de-risking, then rides someone else's commercial machine.
For a clinical-stage peptide developer the "supply chain" is the drug-substance manufacturing + clinical-execution + commercialization stack, and the defining feature is that Zealand has off-loaded the two most capital-intensive links to its partners:
Chokepoints / single-source dependencies: (1) Roche is a near-single point of failure for the lead asset — Zealand's largest value driver is executed, manufactured, and (ex-US) sold by one partner; a Roche strategic pivot away from petrelintide would gut the thesis. (2) Class-wide peptide-API capacity — even partnered, commercial-scale amylin supply competes for the same constrained CDMO/fill-finish capacity as every other GLP-1. (3) Zealand is building its own capability deliberately — a Cambridge (UK) research hub + an AI-supercomputer partnership with the Danish Centre for AI Innovation — i.e. it is reinforcing the discovery link (its moat) while leaving manufacturing/commercial to partners. Names or it didn't happen: the chain is Zealand peptide-design platform → CDMO drug substance (unnamed) → Roche/Boehringer Phase-3 execution + manufacturing → Roche/Boehringer/Novo commercial → payers/patients.
Zealand's moat is narrow but real, and it sits in discovery — not in the lead molecule's profile.
Bargaining power. Weak-to-moderate and asymmetric. Pre-Roche, Zealand needed Roche more than Roche needed Zealand (it had one un-partnered late-stage obesity asset in a field where Roche could have bought alternatives — and indeed Roche also bought 89bio for $3.5B). The deal terms reflect that: Roche took control of manufacturing, ex-US economics, and Phase-3 execution. Post-deal, Zealand's leverage improved — $2.3B cash, a $200M buyback, and two validated partnered assets mean it no longer negotiates from weakness on the next asset. Over patients/payers Zealand has no direct pricing power — that lever sits entirely with Roche/Boehringer.
+clinical swap)Zealand has no product-revenue segmentation (FY2025 revenue is ~99% the one-off Roche upfront). The economically meaningful "segmentation" is the pipeline by value-bearing asset. Revenue is partnership/milestone/royalty-shaped, not product-shaped — so I break it by asset and economic claim rather than by reported segment. All ``; no segments.csv data exists.
| Asset | Modality | Indication | Stage (mid-2026) | Zealand's economics | Why it matters |
|---|---|---|---|---|---|
| Petrelintide | Long-acting amylin analog (once-weekly SC) | Obesity / overweight | Ph2 done → Ph3 H2'26 | 50/50 US+EU profit share; ROW double-digit→high-teens royalty; up to $5.3B total deal value | The lead value driver — ~80%+ of the equity story |
| Petrelintide + enicepatide (CT-388) | Amylin + GLP-1/GIP combo | Obesity (deeper weight loss) | Ph2 init H1'26 | Same 50/50; Zealand paid $350M (offsettable) to co-own | The "combo upside" call option — where petrelintide could close the efficacy gap to CagriSema/tirzepatide |
| Survodutide | Glucagon/GLP-1 dual agonist | Obesity + MASH/MASLD + CV | Ph3 positive (SYNCHRONIZE-1) | High-single→low-double-digit royalty; up to €315M milestones | Second de-risked Phase-3 asset; royalty-only but real; MASH is a distinct large market |
| Glepaglutide | GLP-2 analog (twice-weekly SC autoinjector) | Short bowel syndrome | EU MAA filed; US NDA; EASE-5 confirmatory | Wholly owned (Zealand commercializes) | Nearest-term own approval; orphan/rare = pricing power, modest peak |
| Dapiglutide | GLP-1/GLP-2 dual | Next-gen SBS + obesity | Ph1→Ph2 | Wholly owned | Pipeline-in-a-product follow-on |
| Dasiglucagon (CHI) | Glucagon analog | Congenital hyperinsulinism | NDA resubmission H2'26 | Wholly owned (Zegalogue/severe-hypo out-licensed to Novo) | Small orphan; near-term regulatory event |
| ZP9830 / ZP6590 / ZP6541 | Peptides | Inflammation / GIP | Ph1 / FIH | Wholly owned | Platform-replenishment optionality |
Trend & cause. The direction of travel is decisive: in 18 months Zealand went from a single-late-stage-asset binary to two partnered Phase-3 obesity programs (petrelintide, survodutide) + a filed orphan drug (glepaglutide), funded by a balance sheet that swung from going-concern-watch to DKK 14.5B cash and a buyback. Revenue is lumpy by design — DKK 63M (FY2024) → DKK 9.2B (FY2025) on the Roche upfront, then back to DKK 34M (Q1'26) run-rate until the next milestone (DKK 4.5B / $700M recognized Q2'26 on Phase-3 progression). Do not model this as a P&L company — it's a catalyst-and-milestone cash machine attached to royalty optionality.
+clinical swap)The asset table above is the company. Here is the latest "earnings" read, which for Zealand means the cash position + the clinical prints, not revenue-vs-consensus:
FY2025 (reported 2026-02-19):
Q1 2026 (reported 2026-05):
The clinical print that actually matters — petrelintide ZUPREME-1 (Ph2, topline Mar 2026; full data ADA Jun 2026):
Survodutide SYNCHRONIZE-1 (Ph3, Apr 2026): −16.6% weight loss at 76 weeks vs 3.2% placebo; predominantly fat-mass loss; 34% visceral / 63% liver-fat reduction with minimized lean-mass loss in a pre-specified analysis.
Balance-sheet flags: Healthy. No debt stress noted; cash covers multiple years of the current ~DKK 0.5B/quarter burn, before the milestone inflows. The risk is not solvency — it's whether the assets convert.
No transcripts/ on disk — assessment is `` from earnings-call coverage (Investing.com/Seeking Alpha headlines, Q4'25 + Q1'26).
+clinical swap)Mechanism comps — by target, not by P/E (amylin/incretin obesity peers). Multiples are `` with date or n/a; pre-revenue obesity names trade on pipeline NPV, not earnings multiples, so EV/Sales and P/E are n/a for the pure-plays.
| Company | Ticker | Mkt cap (mid-2026) | Lead obesity asset | Best disclosed efficacy | Multiple basis |
|---|---|---|---|---|---|
| Zealand Pharma | ZEAL.CO | ~$3.3–3.4B | Petrelintide (amylin) | −10.7% / 42wk (Ph2) | Pipeline-NPV; P/E n/a (pre-product) |
| Viking Therapeutics | VKTX | ~$3.59B | VK2735 (GLP-1/GIP, oral+inj) | "best-in-class" Ph2 | NPV; P/E n/a |
| Structure Therapeutics | GPCR | n/a | Aleniglipron (oral GLP-1) | −16.3% placebo-adj / 44wk | NPV; P/E n/a |
| Amgen | AMGN | (large-cap) | MariTide (GLP-1/GIPR antag) | −16.2% / 52wk (Ph2) | Trades on whole-co earnings |
| Metsera | (acquired) | $10B takeout by Pfizer, Nov 2025 | Amylin/GLP-1 | — | M&A comp |
| Novo Nordisk | NVO | (mega-cap) | CagriSema (cagrilintide+sema); amycretin | CagriSema ~20–23%; amycretin 22%/36wk | Operating pharma |
| Eli Lilly | LLY | (mega-cap) | Eloralintide (selective amylin); retatrutide | Eloralintide 9.5–20.1% / 48wk | Operating pharma |
| Roche | (partner) | (mega-cap) | Petrelintide (w/ Zealand) + CT-388 | — | Partner, not comp |
Read: Zealand and Viking sit at near-identical ~$3.3–3.6B caps — but Viking owns 100% of VK2735 while Zealand owns ~50% US of petrelintide. The M&A comps are the bull's anchor: Metsera fetched $10B and Roche paid $3.5B for 89bio — obesity assets command takeout premiums far above Zealand's current cap, if the asset is differentiated. The bear's anchor is the same table read differently: petrelintide's 10.7% sits below eloralintide (up to 20.1%), CagriSema (~20–23%), survodutide (16.6%), MariTide (16.2%) and aleniglipron (16.3%) — it is the lowest-efficacy late-stage obesity asset in its own comp set, carried by tolerability and combo optionality.
Catalyst calendar (what de-risks or kills, and when):
| When | Catalyst | Stakes |
|---|---|---|
| Q2 2026 | $700M / DKK 4.5B Roche milestone recognized (Ph3 progression) | Cash — already largely in the tape |
| H1 2026 | Petrelintide + enicepatide (CT-388) combo Ph2 initiation | Validates the "combo closes the efficacy gap" call option |
| H2 2026 | ZUPREME-2 topline (2nd Ph2) | Confirms or breaks the 10.7%/tolerability profile — highest-information binary |
| H2 2026 | Petrelintide Phase 3 initiation (design + dose disclosed) | Phase-3 dose & comparator choice signal whether Roche is going for magnitude or tolerability positioning |
| H2 2026 | Survodutide SYNCHRONIZE-2 + CV outcomes | Royalty asset de-risking; MASH optionality |
| H2 2026 | Dasiglucagon (CHI) NDA resubmission | Small own-approval |
| 2026–27 | Glepaglutide EU (CHMP opinion) + US NDA decision | Nearest own commercial launch |
| 2027+ | Petrelintide Ph3 readouts | The terminal value event |
Pattern over the last ~18 months:
What the tape tells you: this name trades on binary obesity-data magnitude vs the competitive set and on deal/partnership events — not on financials (the milestone cash barely moves it). The −33% drop on a successful trial is the defining tell: expectations were priced for best-in-class, and 10.7% wasn't it. That de-rating is the setup — the stock has already taken the "undifferentiated" hit; from here it re-rates on combo/ZUPREME-2 surprise or a takeout, and falls further only on a Phase-3 stumble.
Read regulatory/regulatory-findings.md (Step-0): 0 SEC findings — Zealand has no CIK (deregistered 2022), so no EDGAR LR/AAER search is possible. Accounting review is therefore ``-only and IFRS-framed (Danish GAAP/IFRS, not US GAAP).
Accounting-risk read (clinical-stage, partnership-revenue):
Regulatory findings (required sub-section):
"Zealand Pharma" (FDA OR DOJ OR FTC OR EMA OR consent decree OR settlement OR fine OR penalty)): no material enforcement actions, consent decrees, fines, or penalties surfaced. Interactions with FDA/EMA are ordinary-course regulatory submissions (glepaglutide MAA/NDA, dasiglucagon NDA), not enforcement.+clinical swap)For a pre-product company the question is not "what's FY28 EPS" — it's "does cash reach the next value-inflection, and what is the lead asset's risk-adjusted value?" No forecast.ts forecast is logged in this unattended --watchlist run (per skill rules — only log when genuinely committing a base case).
Runway-to-catalyst — comfortably clears. Cash DKK 14.5B (Q1'26) + ~$700M (DKK 4.5B) 2026 Roche milestones → ~DKK 19B expected year-end-2026 liquidity. Against a burn of ~DKK 0.5–0.6B/quarter scaling toward the FY2026 OpEx guide of DKK 2.72–3.3B, that is a 5+ year runway before milestones — and the runway extends with each Phase-3/sales milestone. Cash reaches every near-term catalyst (ZUPREME-2, Phase-3 starts, glepaglutide approvals) with room to spare. Runway is not the risk.
rNPV sketch of the lead (petrelintide, Zealand's ~50% US + ROW royalty share) — illustrative, every input ``, not a precise model (no consensus rNPV sourced):
Analyst anchor for triangulation: consensus Buy (9 buy / 7 hold / 1 sell of ~14), avg target ~DKK 457 (range DKK 300–745; Jefferies DKK505 buy, Deutsche Bank DKK300 hold) vs ~DKK 252–285 spot → ~35% USD / ~60% DKK implied upside. The Street is net-constructive but split — exactly what you'd expect for a de-risked balance sheet wrapped around a contested lead asset.
Bull case. Zealand is a financed call option on the second-largest drug market of the decade, bought at roughly the value of its lead asset alone. Three legs: (1) De-risked balance sheet — $2.3B cash, buyback, partners funding the Phase 3s; this is no longer a dilution-and-pray biotech. (2) Two partnered Phase-3 obesity assets (petrelintide + survodutide) plus a filed orphan drug (glepaglutide) and a combo call option (petrelintide + enicepatide) — multiple shots, not one binary. (3) Tolerability as a real-world wedge: in a market where ~half of GLP-1 patients quit within a year over GI side-effects, a drug with placebo-like tolerability and double-digit loss could win a durable maintenance/foundational niche — and amylin is the consensus "next backbone." The contrarian view the market refuses to see: efficacy magnitude is over-weighted by a market anchored on tirzepatide; adherence-adjusted real-world weight loss may favor a tolerable drug, and obesity is plausibly a multi-winner market (Metsera's $10B takeout says scarcity value for amylin assets is high). Upside is re-rating on ZUPREME-2/combo data or a takeout toward the DKK 450–500 analyst zone.
Bear case (permanent-impairment risks). (1) "Undifferentiated" is structural, not a headline. Petrelintide's 10.7% is the lowest late-stage efficacy in its comp set; if Phase 3 confirms ~10–12% while Lilly's eloralintide (up to 20%) and Novo's amycretin (22%) and CagriSema (~23%) launch, petrelintide becomes a 3rd/4th-choice amylin that struggles for formulary share regardless of tolerability — and Zealand only owns ~50% of US of that. (2) Single-partner dependence: Roche controls execution, manufacturing and ROW commercialization of the lead; Roche has its own obesity pipeline (CT-388/89bio) and could deprioritize petrelintide — Zealand can't control its own destiny on its biggest asset. (3) Expectations baked into the price: even after the −33% drop, ~$3.3B substantially capitalizes petrelintide success — a Phase-3 efficacy or tolerability disappointment re-rates it toward the orphan/survodutide-royalty floor (well below current). Pre-mortem (18 months out, thesis broke): ZUPREME-2 or an early Phase-3 look shows ~10% with tolerability no longer differentiated vs launched competitors; Roche quietly shifts emphasis to its in-house combo; the amylin "scarcity premium" deflates as multiple amylins read out — and Zealand de-rates to a $1.5–2B royalty-stub-plus-cash valuation. Are multiples too high? Not on cash, but the implied lead-asset value leaves little margin for Phase-3 disappointment.
Dismantling the bull case. What structurally breaks the model: Zealand makes money by selling de-risked peptides to Big Pharma and clipping royalties/profit-shares — that only works if the assets are wanted. The lead asset is already flagged "undifferentiated" by the sell-side on its pivotal-supporting data, which means the core value-creation loop (partner pays premium → asset wins share → royalties compound) may be broken at the "wins share" step for petrelintide. Revenue concentration: the equity is ~80% one molecule (petrelintide) controlled by one partner (Roche) that has a competing in-house asset — the single most dangerous concentration in the file. If Roche reallocates, there is no Plan B of equal size. The most dangerous competitor bulls underestimate: Eli Lilly. Not Novo — Lilly, whose eloralintide is a selective amylin (same mechanism as petrelintide) that already showed up to 20.1% — i.e. Lilly can offer petrelintide's mechanism with double the efficacy, plus retatrutide/orforglipron breadth and unmatched manufacturing. That collapses petrelintide's "tolerable amylin" white space. Worst capital-allocation critique: paying Roche $350M for the combo and running a buyback while the lead's differentiation is unproven could read as deploying cash to defend a contested thesis rather than waiting for ZUPREME-2 — though the counter is that the cash is genuinely surplus. What must hold for today's price: petrelintide Phase 3 clears at ≥ current efficacy and the amylin scarcity premium survives multiple competitor readouts and Roche stays committed. If growth/efficacy disappoints 20–30% (Phase-3 ~8% instead of ~11%, or tolerability advantage erodes): the lead-asset rNPV roughly halves and the stock re-rates toward cash + survodutide-royalty + orphan = a ~$1.5–2B floor — meaningful downside from ~$3.3B. Single scenario that permanently impairs: a Phase-3 efficacy or tolerability miss on petrelintide concurrent with a strong Lilly/Novo amylin launch — plausibility moderate, not remote, and it's the scenario the price is least protected against.
A genetics-platform biotech whose lead asset just printed real proof-of-concept in a disease with zero approved drugs — and the stock fell 35% because Vertex's inaxaplin is two years ahead. The bet is whether oral once-daily APOL1 inhibition is a two-horse race or a winner-take-most one.
The first company poised to win an FDA label for "lifespan extension" in any species — a genuinely novel regulatory beachhead on a large, growing owner-pays pet-pharma market — but the bet rides on one not-yet-read-out 1,300-dog trial, a surrogate-style ("reasonable expectation") approval, and a single CMC section still outstanding; WATCHING (privately ownable conviction, no tradeable instrument) with the STAY lifespan readout as the binary.
The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell.